Prospective Single Center Trial to Compare 68Ga-PSMA-11 and Axumin PET/CT (18F-Fluciclovine) for Restaging Prostate Cancer Patients With Biochemical Recurrence After Radical Prostatectomy
Latest Information Update: 31 May 2024
At a glance
- Drugs Fluciclovine 18F (Primary) ; Gallium (68Ga) gozetotide (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- Acronyms PSMA vs AXUMIN
Most Recent Events
- 29 May 2024 According to Blue Earth Diagnostics media release, data from this study will be presented in upcoming presentations by its collaborators at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, to be held June 8 to 11, 2024, in Toronto, Canada.
- 19 Oct 2022 According to Blue Earth Diagnostics media release, data from this study will be presented at the upcoming American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting, from October 23 to 26, 2022.
- 31 May 2020 Results (n=787) of post hoc retrospective analysis from four studies (NCT02940262, NCT03515577, NCT04050215, NCT03582774) presented at the 56th Annual Meeting of the American Society of Clinical Oncology